New drug cocktail aims to shrink liver cancer lung tumors
NCT ID NCT07482670
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—with or without local treatments like surgery or radiation can shrink tumors in people with advanced liver cancer that has spread to the lungs. About 32 participants will receive the drug combination, and some will also get local therapy. The main goal is to see how many patients have their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab (an immunotherapy drug) plus rivoceranib (a targeted therapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that has spread to the lungs, potentially shrinking tumors and extending life.
What could go wrong
This is a small, early-phase study with only 32 participants and no comparison group. The drugs may cause side effects like immune reactions or bleeding, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATECELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••